Search > Obesity
My employer runs this trial

LY4167586 for Obesity

Not yet recruiting at 11 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Eli Lilly and Company

What You Need to Know Before You Apply

What is the purpose of this trial?

The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.

Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.

Who Is on the Research Team?

C1

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

This trial is for people who are overweight or have obesity, with or without type 2 diabetes. Participants must be able to stay in a clinical research unit several times over about a year. Other specific health requirements may apply.

Inclusion Criteria

Part C: Have a hemoglobin (HbA1c) value of ≥6.5 % and ≤10.0%
Part D: To qualify as Chinese for this study, the participant must be at a minimum third-generation Chinese, defined as having all 4 biological grandparents of exclusive Chinese descent and born in China
Part C: Have a BMI ≥25.0 kg/m²
See 6 more

Exclusion Criteria

Have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (except for T2D in Part C), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or constituting a risk when taking the study drug, or interfering with data interpretation

What Are the Treatments Tested in This Trial?

Interventions

  • LY4167586

Trial Overview

The study tests the safety and how the body processes a new drug called LY4167586 compared to a placebo (inactive treatment) in people with obesity or overweight, some of whom may also have type 2 diabetes.

How Is the Trial Designed?

6

Treatment groups

Experimental Treatment

Placebo Group

Group I: Part E LY4167586Experimental Treatment1 Intervention
Group II: Part D LY4167586Experimental Treatment1 Intervention
Group III: Part C LY4167586Experimental Treatment1 Intervention
Group IV: Part B LY4167586Experimental Treatment1 Intervention
Group V: Part A: LY4167586Experimental Treatment1 Intervention
Group VI: Placebo (Part A-E)Placebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials
2,708
Recruited
3,720,000+
Dr. Daniel Skovronsky profile image

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks profile image

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.